This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Career Center   |   Print Page   |   Contact Us   |   Sign In   |   Join SRNT
Slides from the 2016 SRNT Preconference Workshop - Perspectives on Nicotine: Science and Policy
Share |

Following numerous requests for access to the presentations included in the FDA’s pre-conference workshop, Perspectives on Nicotine: Science and Policy, at the SRNT 2016 Annual Meeting, SRNT received permission to post most of the presentations online. We recognize that not all members or meeting attendees could participate in this workshop; therefore, we wanted to make this information broadly available.  To view the slides, please click on the presentation title.  (Note:  only slides that were cleared by presenters for wide dissemination are provided).


This workshop included three parts:

  • Part 1: Presentations to provide brief overviews on the basic science of nicotine, including data from the Population Assessment of Tobacco and Health (PATH) study
  • Part 2: A presentation to provide insights into addressing a different complex public health issue related to harm reduction
  • Part 3: A panel discussion to address the range of policy perspectives on nicotine

Below is a list of the available presentations:


Ø  Perspectives on Nicotine Science and Policy:  Are We Having the Right Debate?
Mitchell Zeller, JD
Center for Tobacco Products, Food and Drug Administration


Ø  Overview of Harms and Risks of Nicotine
Neal Benowitz, MD
University of California, San Francisco


Ø  What the Public Knows and Believes About Nicotine:  Insights from Recent Quantitative and Qualitative Evidence
Sarah Johnson, PhD
Center for Tobacco Products, Food and Drug Administration


Ø  Long-Term Medicinal Nicotine Use after Smoking Cessation
Michael B. Steinberg, MD, MPH, FACP
Rutgers University


Ø  Poly Tobacco Use among Adults and Use of Medications and Tobacco Products in Quit Attempts:  Data from Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study
Nicolette Borek, PhD
Center for Tobacco Products, Food and Drug Administration


Ø  Is a Rose Called by Any Other Name Still a Rose? Applying the Concepts of Harm Reduction to Tobacco
Monica S. Ruiz, PhD, MPH
The George Washington University


# # #

Connect With Us
Membership Management Software Powered by YourMembership  ::  Legal